Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

RECRUITING Phase 3

ZILRETTA in Subjects With Shoulder Osteoarthritis

NCT06269705 · View on ClinicalTrials.gov ↗

Study Summary

Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with glenohumeral OA relative to triamcinolone acetonide injectable suspension, and normal saline placebo * To assess the safety of ZILRETTA in subjects with glenohumeral OA relative to normal saline placebo

Interventions

  • OTHER Placebo
  • DRUG ZILRETTA

Study Locations (20)

Florida

  • Orthopedic Center of Palm Beach City — Atlantis
  • Baptist Health Orthopedic Care - Miami Gardens — Maimi
  • Infinite Clinical Research — Miami
  • Gulfcoast Research Institute — Sarasota
  • Clinical Research of West Florida — Tampa
  • Hospital for Special Services — West Palm Beach

California

  • Horizon Clinical Research — La Mesa
  • Napa Pain Institute — Napa
  • Stanford University - Sports Medicine Clinic — Redwood City

Arizona

  • Onyx Clinical Research — Surprise
  • Tucson Orthopaedic Institute (TOI) - East Office — Tucson

Alabama

  • Alabama Orthopaedic Center- Research — Vestavia Hills

District of Columbia

  • International Spine, Pain & Performance Center — Washington D.C.

Idaho

  • Injury Care Research — Boise

Kansas

  • Kansas City Bone & Joint Clinic - Overland Park — Overland Park

Louisiana

  • Ochsner Sports Medicine Institute — New Orleans

Trial Details

FieldValue
Enrollment Target 150 participants
Start Date 2024-02-05
Est. Completion 2026-08
Phase Phase 3

Sponsor

Pacira Pharmaceuticals

31 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT06269705

The ClinicalTrials.gov registry entry for NCT06269705 describes a study currently listed as recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 150 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Pacira Pharmaceuticals, which has 31 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 1 condition, with Glenohumeral Osteoarthritis appearing as the primary indexed condition, and to 2 interventions — of which Placebo is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT06269705 reports 20 study locations spanning 12 distinct geographic areas — top geographies include Florida, California, Arizona. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT06269705 about?

NCT06269705 is a clinical study titled "ZILRETTA in Subjects With Shoulder Osteoarthritis". Primary Objective: To assess the efficacy of ZILRETTA on pain following an intra-articular (IA) injection in subjects with glenohumeral osteoarthritis (OA) relative to normal saline placebo Secondary Objective: * To assess the efficacy of ZILRETTA on pain following an IA injection in subjects with...

What is the current status of trial NCT06269705?

This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 150 participants. The study started on 2024-02-05. Estimated completion is 2026-08.

What conditions does trial NCT06269705 study?

This clinical trial studies the following conditions: Glenohumeral Osteoarthritis. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT06269705?

The interventions under investigation include: Placebo (OTHER), ZILRETTA (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT06269705?

This trial is sponsored by Pacira Pharmaceuticals, which has 31 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT06269705 being conducted?

This trial has 20 study locations across Alabama, Arizona, California, District of Columbia, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial